AP3529A - Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors - Google Patents

Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors

Info

Publication number
AP3529A
AP3529A AP2014007378A AP2014007378A AP3529A AP 3529 A AP3529 A AP 3529A AP 2014007378 A AP2014007378 A AP 2014007378A AP 2014007378 A AP2014007378 A AP 2014007378A AP 3529 A AP3529 A AP 3529A
Authority
AP
ARIPO
Prior art keywords
hydroxymethylaryl
pyrrolotriazines
substituted
alk1 inhibitors
alk1
Prior art date
Application number
AP2014007378A
Other languages
English (en)
Other versions
AP2014007378A0 (en
Inventor
Juergen Klar
Verena Voehringer
Joachim Telser
Mario Lobell
Frank Suesmeier
Volkhart Min-Jian Li
Michael Boettger
Stefan Golz
Dieter Lang
Karl-Heinz Schlemmer
Thomas Schlange
Andreas Schall
Wenlang Fu
Original Assignee
Bayer Ip Gmbh
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47436537&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP3529(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Ip Gmbh, Bayer Pharma AG filed Critical Bayer Ip Gmbh
Publication of AP2014007378A0 publication Critical patent/AP2014007378A0/xx
Application granted granted Critical
Publication of AP3529A publication Critical patent/AP3529A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2014007378A 2011-07-01 2012-06-26 Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors AP3529A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161503840P 2011-07-01 2011-07-01
EP12161547 2012-03-27
PCT/EP2012/062366 WO2013004551A1 (en) 2011-07-01 2012-06-26 Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors

Publications (2)

Publication Number Publication Date
AP2014007378A0 AP2014007378A0 (en) 2014-01-31
AP3529A true AP3529A (en) 2016-01-11

Family

ID=47436537

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2014007378A AP3529A (en) 2011-07-01 2012-06-26 Hydroxymethylaryl-substituted pyrrolotriazines as alk1 inhibitors

Country Status (25)

Country Link
US (1) US9040691B2 (es)
EP (1) EP2726482B1 (es)
JP (1) JP5955953B2 (es)
KR (1) KR20140036269A (es)
CN (1) CN103764657B (es)
AP (1) AP3529A (es)
AR (1) AR087017A1 (es)
AU (1) AU2012280508A1 (es)
BR (1) BR112014000049A2 (es)
CA (1) CA2840518A1 (es)
CO (1) CO6870031A2 (es)
CU (1) CU20130170A7 (es)
DO (1) DOP2013000300A (es)
EA (1) EA023775B1 (es)
EC (1) ECSP13013120A (es)
ES (1) ES2598027T3 (es)
GT (1) GT201300313A (es)
IL (1) IL229533A0 (es)
MA (1) MA35601B1 (es)
MX (1) MX2013014315A (es)
PE (1) PE20140570A1 (es)
PH (1) PH12013502695A1 (es)
SG (1) SG195100A1 (es)
UY (1) UY34167A (es)
WO (1) WO2013004551A1 (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012253653A1 (en) 2011-05-10 2013-05-02 Gilead Sciences, Inc. Fused heterocyclic compounds as sodium channel modulators
NO3175985T3 (es) 2011-07-01 2018-04-28
TWI622583B (zh) 2011-07-01 2018-05-01 基利科學股份有限公司 作為離子通道調節劑之稠合雜環化合物
AU2012294342B2 (en) 2011-08-10 2017-07-27 Lankenau Institute For Medical Research Methods and compositions for the treatment of autoimmune and inflammatory diseases
CN104080789B (zh) * 2012-01-31 2016-05-11 南京奥昭生物科技有限公司 作为布鲁顿酪氨酸激酶抑制剂的环状分子
US11447568B2 (en) 2014-04-10 2022-09-20 Lankenau Institute For Medical Research Methods and compositions for the treatment of ocular diseases and disorders
WO2015181097A1 (en) 2014-05-28 2015-12-03 Bayer Cropscience Ag Process for preparing thiazole derivatives
EP3209665B1 (en) * 2014-10-22 2019-08-14 Bristol-Myers Squibb Company Substituted pyrrolotriazine amine compounds as pi3k inhibitors
ES2807785T3 (es) 2014-10-22 2021-02-24 Bristol Myers Squibb Co Compuestos de heteroarilamina bicíclicos como inhibidores de pi3k
JP2017535573A (ja) 2014-11-25 2017-11-30 バイエル ファーマ アクチエンゲゼルシャフト 置換されたピリドベンゾジアゼピノン誘導体およびそれの使用
CA2982664A1 (en) 2015-04-16 2016-10-20 Merck Patent Gmbh 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one derivatives
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
CN114456176B (zh) 2016-03-28 2024-08-30 因赛特公司 作为tam抑制剂的吡咯并三嗪化合物
CN109111447A (zh) 2017-06-23 2019-01-01 中国科学院上海药物研究所 7-位取代吡咯并三嗪类化合物或其药学上可用的盐，及其制备方法和用途
KR102739325B1 (ko) 2017-09-27 2024-12-09 인사이트 코포레이션 Tam 억제제로서 유용한 피롤로트리아진 유도체의 염
US11241438B2 (en) 2018-06-29 2022-02-08 Incyte Corporation Formulations of an AXL/MER inhibitor
EP4424312A3 (en) 2019-04-12 2025-01-08 Blueprint Medicines Corporation Pyrrolotriazine derivatives for treating kit- and pdgfra-mediated diseases
PH12022552347A1 (en) 2020-03-06 2024-01-29 Incyte Corp Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors
JP2025540906A (ja) 2022-11-04 2025-12-17 ブリストル－マイヤーズ スクイブ カンパニー Ｒｅｔ－ｌｄｄタンパク質阻害剤

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061882A2 (en) * 2005-11-18 2007-05-31 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ303660B6 (cs) * 1999-05-21 2013-02-13 Bristol-Myers Squibb Company Pyrrolotriazin a farmaceutický prostredek s jeho obsahem
US7375087B2 (en) 2002-08-08 2008-05-20 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US7148226B2 (en) 2003-02-21 2006-12-12 Agouron Pharmaceuticals, Inc. Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
UY28931A1 (es) 2004-06-03 2005-12-30 Bayer Pharmaceuticals Corp Derivados de pirrolotriazina utiles para tratar trastornos hiper-proliferativos y enfermedades asociadas con angiogenesis
DE102005042742A1 (de) * 2005-09-02 2007-03-08 Schering Ag Substituierte Imidazo[1,2b]pyridazine als Kinase-Inhibitoren, deren Herstellung und Verwendung als Arzneimittel
JP5116687B2 (ja) * 2005-11-02 2013-01-09 バイエル・ファルマ・アクチェンゲゼルシャフト がんおよび他の過剰増殖性疾患の処置のためのピロロ［２，１−ｆ］［１，２，４］トリアジン−４−イルアミンＩＧＦ−１Ｒキナーゼ阻害剤
KR101461680B1 (ko) 2005-12-02 2014-11-19 바이엘 헬스케어 엘엘씨 과다-증식성 장애 및 맥관형성과 관련된 질환의 치료에유용한 치환된 4-아미노-피롤로트리아진 유도체
PE20070855A1 (es) 2005-12-02 2007-10-14 Bayer Pharmaceuticals Corp Derivados de 4-amino-pirrolotriazina sustituida como inhibidores de quinasas
TW200801008A (en) 2005-12-29 2008-01-01 Abbott Lab Protein kinase inhibitors
KR20090075714A (ko) * 2006-10-30 2009-07-08 노파르티스 아게 소염제로서의 헤테로시클릭 화합물
SI2114980T1 (sl) 2007-01-12 2012-11-30 Biocryst Pharm Inc Protivirusni nukleozidni analogi
US8124759B2 (en) 2007-05-09 2012-02-28 Abbott Laboratories Inhibitors of protein kinases
PE20090506A1 (es) * 2007-07-26 2009-05-28 Novartis Ag DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4
MX2010004244A (es) * 2007-10-17 2010-04-30 Novartis Ag Derivados de imidazo [i,2-a]-piridina utiles como inhibidores de cinasa tipo activina (alk).
EP2300469B1 (en) * 2008-05-13 2015-06-24 Novartis AG Fused nitrogen containing heterocycles and compositions thereof as kinase inhibitors
WO2010126960A1 (en) 2009-04-29 2010-11-04 Locus Pharmaceuticals, Inc. Pyrrolotriazine compounds

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007061882A2 (en) * 2005-11-18 2007-05-31 Bristol-Myers Squibb Company Pyrrolotriazine kinase inhibitors
EP1873157A1 (en) * 2006-06-21 2008-01-02 Bayer Schering Pharma Aktiengesellschaft Pyrazolopyrimidines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

Also Published As

Publication number Publication date
UY34167A (es) 2013-01-31
JP5955953B2 (ja) 2016-07-20
DOP2013000300A (es) 2014-02-28
EP2726482B1 (en) 2016-07-20
ES2598027T3 (es) 2017-01-24
PH12013502695A1 (en) 2019-06-14
CO6870031A2 (es) 2014-02-20
CN103764657B (zh) 2016-05-25
EA023775B1 (ru) 2016-07-29
PE20140570A1 (es) 2014-04-28
WO2013004551A1 (en) 2013-01-10
CA2840518A1 (en) 2013-01-10
SG195100A1 (en) 2013-12-30
NZ619453A (en) 2016-01-29
AU2012280508A1 (en) 2013-12-12
CU20130170A7 (es) 2014-04-24
BR112014000049A2 (pt) 2017-02-07
CU24146B1 (es) 2016-02-29
JP2014525902A (ja) 2014-10-02
GT201300313A (es) 2014-11-13
EA201490103A1 (ru) 2014-06-30
AR087017A1 (es) 2014-02-05
ECSP13013120A (es) 2014-02-28
AP2014007378A0 (en) 2014-01-31
US9040691B2 (en) 2015-05-26
IL229533A0 (en) 2014-01-30
US20140256718A1 (en) 2014-09-11
CN103764657A (zh) 2014-04-30
MX2013014315A (es) 2014-01-31
MA35601B1 (fr) 2014-11-01
KR20140036269A (ko) 2014-03-25
EP2726482A1 (en) 2014-05-07

Similar Documents

Publication Publication Date Title
IL284539A (en) Heterocycloamines as PI3K inhibitors
IL229533A0 (en) Hydroxymethylaryl-converted pyrrolotriazins as 1alk inhibitors
PL2710007T3 (pl) Inhibitory kinazy
IL232958A (en) Kinase inhibitors
IL228103A0 (en) Amino-quinolines as kinase inhibitors
IL229028A0 (en) Kinase inhibitors
PT2694510E (pt) Imidazopiridazinas como inibidores da akt quinase
IL232959A (en) Kinase inhibitors
IL235919A0 (en) inhibitors of fbxo3
GB201113689D0 (en) Novel PDE4 inhibitors
ZA201308697B (en) Hydroxymethylaryl-substituted pyprolotriazines as alk1 inhibitors
GB201120474D0 (en) Inhibitors
GB201104399D0 (en) Novel inhibitors
GB201223308D0 (en) Enzyme inhibitors